Gold nanorods deliver a one-two to cancer; Antares Pharma submits methotrexate NDA;

Cancer

> Gold nanorods that assemble themselves respond to a light trigger and deliver drug and a blast of heat right to cancer cells in a two-for-one attack. Article

> Australian researchers have created a nanoparticle that could mean oral delivery of the cancer drug 5-fluorouracil (5-FU), getting treatment to the gut for colorectal cancer. Article

Rheumatoid arthritis

> Antares Pharma ($ATRS) has submitted an NDA to the FDA for Otrexup for the treatment of rheumatoid arthritis and psoriasis. Otrexup delivers methotrexate under the skin using Medi-Jet technology. Press release

Drug delivery systems

> Researchers from Northern Ireland are developing microneedle arrays from hydrogels. Abstract

> Teva Pharmaceutical Industries ($TEVA) has dropped $300 million plans for a warehouse and IT center in Philadelphia and is focusing its plans on drug delivery of older products. Article

> University of Houston researchers are developing a system to deliver lifesaving drugs and fluids on the battlefield after traumatic injury. Press release

Licensing and patent news

> Cosmo Pharmaceuticals has signed an agreement to develop oral extended-release versions of AIMM Therapeutics' monoclonal antibodies, using its MMX technology. Press release

> Aphios has received notification of allowance in the U.S. for a patent for its oral microsphere and nanosphere insulin-delivery systems. Press release

> Under the terms of an agreement with Titan Pharmaceuticals ($TTNP), Braeburn Pharmaceuticals has gained U.S. and Canadian rights to the investigational product Probuphine, a subdermal delivery system for buprenorphine in opioid dependence. Press release

And Finally… A microactuator that flexes like a finger could pump drugs. Article | Press release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.